Researchers report a method that engineers bacteria to convert post‑consumer plastic bottles into L‑DOPA, the frontline medication for Parkinson’s disease. The study describes a biosynthetic pathway that degrades polyethylene feedstock and funnels intermediates into microbial L‑DOPA production, marking the first demonstration of turning waste plastic into a therapeutic for a neurological disorder. The team optimized microbial enzymes and fermentation conditions to yield pharmacologically relevant L‑DOPA from plastic-derived substrates; the work was described in a recent research report. L‑DOPA is the immediate precursor to dopamine and remains a standard symptomatic therapy in Parkinson’s care. The authors position this as a proof‑of‑concept for circular bio‑manufacturing: it links waste‑feedstock valorization with drug production. Practical translation will require scale‑up, impurity profiling, and regulatory review for manufacturing from nontraditional feedstocks.